PYXS
Pyxis Oncology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PYXS
Pyxis Oncology, Inc.
A diversified oncology company focused on developing therapeutics to target difficult-to-treat cancers
321 Harrison Avenue, Boston, Massachusetts 02118
--
Pyxis Oncology, Inc., was incorporated in Delaware on June 11, 2018. The company is a clinical-stage oncology company focused on developing a multi-modal portfolio of next-generation therapies to target difficult-to-treat cancers and improve the quality of life of patients. The goal of the product candidates developed by the company is to directly kill tumor cells and address the underlying pathology caused by cancer, resulting in uncontrolled proliferation and immune evasion.
Company Financials
EPS
PYXS has released its 2025 Q3 earnings. EPS was reported at -0.35, versus the expected -0.34, missing expectations. The chart below visualizes how PYXS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
